What's Happening?
Researchers at Weill Cornell Medicine have identified a previously unknown DNA mechanism that may explain the development of approximately 20% of human cancers. The study, published in Nature on October 28, 2026, reveals that mutations in the BAF protein
complex, common in various cancers, promote tumor growth by altering the three-dimensional organization of DNA within cells. This disruption leads to changes in gene activity related to cell division. Specifically, when BAF activity is impaired, a regulatory protein called CTCF gains increased access to DNA sites that are normally less accessible. This widespread increase in CTCF binding reorganizes DNA loops and folds, disrupting normal gene-regulatory element interactions and ultimately accelerating cell division. The team successfully reversed the cancer-promoting effects of BAF mutations in an animal model by blocking CTCF, suggesting its critical role in this process. Additionally, two other protein complexes, PBAF and ISWI, were found to cooperate with CTCF, and their removal also blocked the effects of BAF mutations in experimental models.
Why It's Important?
This discovery is significant because it establishes a unifying mechanism for one of the most common classes of cancer mutations, which have previously been difficult to explain across diverse cancer types. By identifying CTCF, PBAF, and ISWI as key players, the research provides novel molecular targets for the development of future cancer therapies. Cancers with BAF mutations affect various tissues, including the breast, ovaries, liver, and lymphatic system, indicating that these findings could have broad implications for a substantial portion of cancer patients. The ability to reverse cancer-promoting effects in animal models by targeting these proteins offers a promising avenue for drug development. This research could lead to more effective and targeted treatments for patients whose cancers are driven by these specific genetic alterations, potentially improving patient outcomes and reducing the burden of these diseases.
What's Next?
The immediate next steps for the researchers involve further investigation into the precise mechanisms by which increased CTCF binding alters the genome. Understanding these detailed molecular changes is crucial for developing effective interventions. The team aims to identify drugs that can safely and effectively block this process in humans. While the current experiments have identified promising molecular targets, it has not yet been established whether blocking these proteins can safely treat cancer in human patients. Future research will focus on preclinical drug development and testing to assess the therapeutic potential and safety profile of compounds that target CTCF, PBAF, or ISWI. This will involve moving from animal models to more advanced studies, eventually aiming for clinical trials to translate these findings into tangible treatments for cancer patients.
Beyond the Headlines
This research challenges previous assumptions about how the BAF complex functions, as its loss was unexpectedly found to make DNA more accessible to CTCF, rather than less. This paradigm shift in understanding DNA accessibility and its regulation in cancer opens new avenues for basic science research into chromatin architecture and gene expression. The identification of a shared mechanism across different cancer types highlights the potential for developing broad-spectrum therapies that could be applicable to various malignancies, moving beyond tissue-specific treatments. Furthermore, the study underscores the complexity of genomic regulation and how subtle changes in protein interactions can have profound effects on cellular behavior, leading to disease. The ethical implications of targeting fundamental cellular processes like DNA organization will also need careful consideration as potential therapies advance, ensuring specificity and minimizing off-target effects.
